Back to Authors

Bryant, Sandra C.

0009-0008-3056-9093

Mayo Clinic

Mayo Clinic

Citations 45

Plasma Ceramides
Meeusen, Jeffrey W. , Bryant, Sandra C. , Baudhuin, Linnea M. , Berger, Peter B. , Jaffe, Allan S. , Donato, Leslie J. , Jaffe, Allan S.

Arteriosclerosis, Thrombosis, and Vascular Biology | June 14, 2018 | Volume: 38 | Issue: 8 | Pages: 1933-1939

10.1161/atvbaha.118.311199 Get It

Objective— Ceramides are sphingolipids involved with cellular signaling. Synthesis of ceramides occurs in all tissues. Ceramides accumulate within tissues and the blood plasma during metabolic dysfunction, dyslipidemia, and inflammation. Elevations of ceramides are predictive of cardiovascular mortality. We sought to verify the utility of plasma concentrations of 4 ceramides: N-palmitoyl-sphingosine [Cer(16:0)], N-stearoyl-sphingosine [Cer(18:0)], N-nervonoyl-sphingosine [Cer(24:1)], and N-lignoceroyl-sphingosine [Cer(24:0)] in predicting major adverse cardiovascular events in a diverse patient population referred for coronary angiography. Approach and Results— Plasma ceramides were measured in 495 participants before nonurgent coronary angiography. Coronary artery disease, defined as >50% stenosis in ≥1 coronary artery, was identified 265 (54%) cases. Ceramides were not significantly associated with coronary artery disease. Patients were followed for a combined primary end point of myocardial infarction, percutaneous intervention, coronary artery bypass, stroke, or death within 4 years. Ceramides were significantly predictive of outcomes after adjusting for age, sex, body mass index, hypertension, smoking, LDL (low-density lipoprotein) cholesterol, HDL (high-density lipoprotein) cholesterol, triglycerides, serum glucose, and family history of coronary artery disease. The fully adjusted per SD hazard ratios (95% confidence interval) were 1.50 (1.16–1.93) for Cer(16:0), 1.42 (1.11–1.83) for Cer(18:0), 1.43 (1.08–1.89) for Cer(24:1), and 1.58 (1.22–2.04) for the ceramide risk score. Conclusions— Elevated plasma concentrations of ceramides are independently associated with major adverse cardiovascular events in patients with and without coronary artery disease.
Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis
Dubey, Divyanshu , Pittock, Sean J. , Kelly, Cecilia R. , McKeon, Andrew , López‐Chiriboga, A. Sebastian , Lennon, Vanda A. , Gadoth, Avi , Bryant, Sandra C. , Klein, Christopher J. , Aksamit, Allen J. , Toledano, Michel , Tillema, Jan‐Mendelt , Smith, Carin Y. , Pittock, S J , Klein, Christopher J , McKeon, Andrew , Dubey, Divyanshu , Boeve, Bradley F. , Flanagan, Eoin P.

Annals of Neurology | January 2, 2018 | Volume: 83 | Issue: 1 | Pages: 166-177

10.1002/ana.25131 Get It

Objective To evaluate the incidence and prevalence of autoimmune encephalitis and compare it to that of infectious encephalitis. Methods We performed a population‐based comparative study of the incidence and prevalence of autoimmune and infectious encephalitis in Olmsted County, Minnesota. Autoimmune encephalitis diagnosis and subgroups were defined by 2016 diagnostic criteria, and infectious encephalitis diagnosis required a confirmed infectious pathogen. Age‐ and sex‐adjusted prevalence and incidence rates were calculated. Patients with encephalitis of uncertain etiology were excluded. Results The prevalence of autoimmune encephalitis on January 1, 2014 of 13.7/100,000 was not significantly different from that of all infectious encephalitides (11.6/100,000; p = 0.63) or the viral subcategory (8.3/100,000; p = 0.17). The incidence rates (1995–2015) of autoimmune and infectious encephalitis were 0.8/100,000 and 1.0/100,000 person‐years, respectively ( p = 0.58). The number of relapses or recurrent hospitalizations was higher for autoimmune than infectious encephalitis ( p = 0.03). The incidence of autoimmune encephalitis increased over time from 0.4/100,000 person‐years (1995–2005) to 1.2/100,000 person‐years (2006–2015; p = 0.02), attributable to increased detection of autoantibody‐positive cases. The incidence (2.8 vs 0.7/100,000 person‐years, p = 0.01) and prevalence (38.3 vs 13.7/100,000, p = 0.04) of autoimmune encephalitis was higher among African Americans than Caucasians. The prevalence of specific neural autoantibodies was as follows: myelin oligodendrocyte glycoprotein, 1.9/100,000; glutamic acid decarboxylase 65, 1.9/100,000; unclassified neural autoantibody, 1.4/100,000; leucine‐rich glioma‐inactivated protein 1, 0.7/100,000; collapsin response‐mediator protein 5, 0.7/100,000; N‐methyl‐D‐aspartate receptor, 0.6/100,000; antineuronal nuclear antibody type 2, 0.6/100,000; and glial fibrillary acidic protein α, 0.6/100,000. Interpretation This study shows that the prevalence and incidence of autoimmune encephalitis are comparable to infectious encephalitis, and its detection is increasing over time. Ann Neurol 2018;83:166–177
Genetic Variation in Statin Intolerance and a Possible Protective Role for UGT1A1
Kaleta, Erin, Bryant, Sandra C. , Spears, Grant M. , Train, Laura, Peterson, Sandra E. , Lennon, Vanda A. , Kopecky, Stephen L. , Baudhuin, Linnea M. , V Willrich, Maria Alice, Kaleta, Erin J, Train, Laura J, Willrich, Maria Alice V.

Pharmacogenomics | December 6, 2017 | Volume: 19 | Issue: 2 | Pages: 83-94

10.2217/pgs-2017-0146 Get It

Paired comparison of therapeutic plasma exchange using the Fenwal Amicus versus TerumoBCTSpectra Optia
Burgstaler, Edwin A. , Bryant, Sandra C. , Winters, Jeffrey L. , Winters, Jeffrey L

Journal of Clinical Apheresis | September 23, 2017 | Volume: 33 | Issue: 3 | Pages: 265-273

10.1002/jca.21589 Get It

PurposeTerumo BCT Spectra Optia (O) and Fenwal Amicus (A) can perform therapeutic plasma exchange (TPE). We compared these systems in a prospective, randomized, crossover study of 81 paired procedures. Primary objective was to determine if there was a difference in platelet loss between the instruments. Secondary objectives were to determine differences in procedure time (PT), plasma removal efficiency (PRE 1), plasma removal rate (PRR), and fluid balance (FB).MethodsFifty‐seven adults undergoing 162 procedures were included. Diagnoses included neurologic, nephrologic, and hematologic diseases. Replacement fluids included 5% normal serum albumin and/or fresh frozen plasma. The first instrument (randomized) established the inlet flow rate for the second with a maximum inlet rate of 120 ml/min. Spun HCT was used to program the procedure. One plasma volume was exchanged, for both instruments. Multivariable general estimating equations were used to assess the relationship between the outcome variables with machine after adjusting for covariates, with P values <.05 significant.ResultsMedian total blood volume (4,775 mL‐A, 4,775 mL‐O) and preprocedure spun HCT (33%‐A, 34%‐O) were not statistically different. The plasma removed (3196 mL‐A, 3120 mL‐O), PLT in waste plasma (0.62 × 1011‐A, 0.33 × 1011‐O), PLT decline (8.5%‐A, 6.5%‐O), and PRR (48.1 mL/min‐A, 49.2 mL/min‐O) were not statistically different. There were statistically significant, but clinically irrelevant, differences in PLT CE1 (6.2%‐A, 3.6%‐O), PRE 1 (85.3%‐A, 83.9%‐O), FB (+2 mL‐A,+15 mL‐O), and PT (71 min‐A, 71 min‐O).ConclusionsStatistical differences were seen but none were of a magnitude to be clinically relevant, indicating comparable TPE performance.
Impact of Glucose Meter Error on Glycemic Variability and Time in Target Range During Glycemic Control After Cardiovascular Surgery
Karon, Brad S. , Meeusen, Jeffrey W. , Bryant, Sandra C.

Journal of Diabetes Science and Technology | August 26, 2015 | Volume: 10 | Issue: 2 | Pages: 336-342

10.1177/1932296815602099 Get It

Background: We retrospectively studied the impact of glucose meter error on the efficacy of glycemic control after cardiovascular surgery. Method: Adult patients undergoing intravenous insulin glycemic control therapy after cardiovascular surgery, with 12-24 consecutive glucose meter measurements used to make insulin dosing decisions, had glucose values analyzed to determine glycemic variability by both standard deviation (SD) and continuous overall net glycemic action (CONGA), and percentage glucose values in target glucose range (110-150 mg/dL). Information was recorded for 70 patients during each of 2 periods, with different glucose meters used to measure glucose and dose insulin during each period but no other changes to the glycemic control protocol. Accuracy and precision of each meter were also compared using whole blood specimens from ICU patients. Results: Glucose meter 1 (GM1) had median bias of 11 mg/dL compared to a laboratory reference method, while glucose meter 2 (GM2) had a median bias of 1 mg/dL. GM1 and GM2 differed little in precision (CV = 2.0% and 2.7%, respectively). Compared to the period when GM1 was used to make insulin dosing decisions, patients whose insulin dose was managed by GM2 demonstrated reduced glycemic variability as measured by both SD (13.7 vs 21.6 mg/dL, P < .0001) and CONGA (13.5 vs 19.4 mg/dL, P < .0001) and increased percentage glucose values in target range (74.5 vs 66.7%, P = .002). Conclusions: Decreasing glucose meter error (bias) was associated with decreased glycemic variability and increased percentage of values in target glucose range for patients placed on intravenous insulin therapy following cardiovascular surgery.
Relationship of Genetic Variation in the Serotonin Transporter Gene ( SLC6A4 ) and Congenital and Acquired Cardiovascular Diseases
Moyer, Ann M. , Walker, Denise L., Avula, Rajeswari, Kung, Simon , Bryant, Sandra C. , Edwards, Kelly K., Black, John L. , Karpyak, Victor M. , Shinozaki, Gen , Jowsey‐Gregoire, Sheila G. , Ehlers, Shawna L. , Romanowicz, Magdalena , Litzow, Mark R. , Rundell, James R., Hooten, W. Michael , Baudhuin, Linnea M. , Lapid, Maria I. , Hogan, William J. , Karpyak, Victor

Genetic Testing and Molecular Biomarkers | February 11, 2015 | Volume: 19 | Issue: 3 | Pages: 115-123

10.1089/gtmb.2014.0250 Get It

Outcomes of plasma exchange in patients with transplant‐associated thrombotic microangiopathy based on time of presentation since transplant
Mulay, Sudhanshu , Kreuter, Justin D. , Bryant, Sandra C. , Elliott, Michelle A. , Gastineau, Dennis A. , Winters, Jeffrey L. , Hogan, William J.

Journal of Clinical Apheresis | September 17, 2014 | Volume: 30 | Issue: 3 | Pages: 147-153

10.1002/jca.21352 Get It

Transplant‐associated thrombotic microangiopathy (TA‐TMA) is a rare clinical syndrome associated with significant mortality. Although the use of plasma exchange (PE) in TA‐TMA continues to be explored, evidence for its efficacy is debated. We performed a single institution, retrospective study to evaluate the efficacy of PE in treating TA‐TMA patients. Special attention was given to efficacy in relation to the timing of presentation with TA‐TMA since transplant. Thirty‐three patients diagnosed with TA‐TMA and treated with PE between January 1999 and December 2010 were included in the study. Clinical improvement was seen in eight patients (24%); four patients achieved complete resolution while the remaining four achieved partial resolution. All‐cause day‐30 and day‐100 mortality was 33 and 55%, respectively. There was a trend toward a better outcome (complete/partial) for those presenting ≥ 100 days after transplantation (42%) vs. < 100 days after transplantation (14%; P‐value = 0.15). Similarly, those presenting at ≥ 100 days had better, but not significantly, 30‐day and 100‐day all‐cause mortality rates (17 and 33%, respectively) than those presenting at < 100 days (43 and 67%, respectively) (P‐value = 0.25 and 0.08, for 30‐ and 100‐day all‐cause mortality, respectively). This is the first study looking at the efficacy of PE while considering the time of presentation since transplantation and is one of the largest single institution series of TA‐TMA. The overall efficacy of PE is poor; however, patients who present with TA‐TMA ≥100 days after transplant may have better outcome and lower mortality. J. Clin. Apheresis 30:147–153, 2015. © 2014 Wiley Periodicals, Inc.
Development and Initial Validation of a Project-Based Rubric to Assess the Systems-Based Practice Competency of Residents in the Clinical Chemistry Rotation of a Pathology Residency
Vitek, Carolyn R. Rohrer , Dale, Jane C., Homburger, Henry A., Bryant, Sandra C. , Saenger, Amy K., Karon, Brad S. , Vitek, Carolyn R

Archives of Pathology and Laboratory Medicine | May 30, 2014 | Volume: 138 | Issue: 6 | Pages: 809-813

10.5858/arpa.2013-0046-oa Get It

Context.— Systems-based practice (SBP) is 1 of 6 core competencies required in all resident training programs accredited by the Accreditation Council for Graduate Medical Education. Reliable methods of assessing resident competency in SBP have not been described in the medical literature. Objective.— To develop and validate an analytic grading rubric to assess pathology residents' analyses of SBP problems in clinical chemistry. Design.— Residents were assigned an SBP project based upon unmet clinical needs in the clinical chemistry laboratories. Using an iterative method, we created an analytic grading rubric based on critical thinking principles. Four faculty raters used the SBP project evaluation rubric to independently grade 11 residents' projects during their clinical chemistry rotations. Interrater reliability and Cronbach α were calculated to determine the reliability and validity of the rubric. Project mean scores and range were also assessed to determine whether the rubric differentiated resident critical thinking skills related to the SBP projects. Results.— Overall project scores ranged from 6.56 to 16.50 out of a possible 20 points. Cronbach α ranged from 0.91 to 0.96, indicating that the 4 rubric categories were internally consistent without significant overlap. Intraclass correlation coefficients ranged from 0.63 to 0.81, indicating moderate to strong interrater reliability. Conclusions.— We report development and statistical analysis of a novel SBP project evaluation rubric. The results indicate the rubric can be used to reliably assess pathology residents' critical thinking skills in SBP.
Infusion technique of hematopoietic progenitor cells and related adverse events (CME)
Mulay, Sudhanshu , Greiner, Carl, Mohr, Amy, Bryant, Sandra C. , Lingineni, Ravi K., Padley, Doug, Gastineau, Dennis A., Jacob, Eapen K., Hogan, William J. , Gastineau, Dennis A.

Transfusion | February 17, 2014 | Volume: 54 | Issue: 8 | Pages: 1997-2003

10.1111/trf.12572 Get It

BackgroundThe use of hematopoietic progenitor cell (HPC) transplant has risen over the past two decades. A variety of adverse events (AEs) of varying severity have been noted during HPC infusions. These AEs have been associated with several factors such as the amount of dimethyl sulfoxide and white blood cells in the HPC product. We performed a single‐institution retrospective analysis to determine the effect of two different HPC infusion techniques, manual push with syringes versus infusion from bags with the aid of gravity, on the occurrence of infusion‐related AEs.Study Design and MethodsInfusions between December 2008 and November 2010 involving peripheral blood HPCs were reviewed. Pertinent clinical and HPC product–related information was recorded. Data were analyzed to determine the incidence of infusion‐related AEs and its association with patient and product‐related variables.ResultsWe found 461 AEs in 645 patients during the study period. A total of 325 (50%) experienced at least one AE. Flushing was the most common type of AE followed by nausea and hypertension. The use of syringe infusion was more commonly associated with AEs (odds ratio, 1.82 [95% confidence interval, 1.32‐2.50]; p = 0.002). Other independent risk factors were cryopreserved products and the amount of polymorphonuclear leukocytes in the product.ConclusionTo our knowledge, this is the first study examining the effect of two different infusion techniques on infusion‐related AEs. Our findings suggest that the use of bags for infusion protected the patients from AEs.